Oragenics (OGEN) 10-Q2020 Q2 Quarterly report

Filed: 14 Aug 20, 4:11pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: academic, Aid, alternative, analytical, antibody, Aragen, assay, assessed, assist, benchmark, binding, Bioscience, borrowing, breach, building, capsule, cease, ceased, challenge, Chemistry, Chinese, CHO, CMC, Cooperation, Corona, dataset, deferral, Department, diarrhea, digit, discretion, EGI, Eleszto, emerge, exploit, extended, extensive, forgivable, furlough, Genetika, geographic, geography, Hamster, heightened, HHS, home, hospital, ht, immunogenic, immunogenicity, impede, indirectly, ineligible, infected, inserted, insertion, insolvency, intercompany, interrupt, low, lump, man, monoclonal, monthly, mouse, movement, mutually, neutralization, neutralizing, nongovernmental, nonrefundable, noteholder, notice, NTI, optimize, outer, Ovary, past, Paycheck, PCT, plaque, PPP, preliminary, prioritization, PRNT, pro, prolonged, rata, recombinant, recruit, refine, regional, regular, retrieval, secondary, sequence, Sigma, signature, sourcing, stay, stockholder, subscription, successful, successfully, summer, temporary, toxicology, transfer, trimeric, uncured, underway, unforgiven, upfront, withdrew, workforce, written

Removed: active, ActoBio, addressing, adherence, aware, Biologic, BLA, broadly, cavity, CDC, center, chemotherapy, collection, commonly, conducted, continuing, conventional, damaged, designed, enrolled, enrollment, etiology, Europe, European, evaluate, exclusivity, expedite, facilitate, Factor, fast, feedback, incidence, inflammation, influence, initiated, Intrexon, Key, lining, maturity, medical, mucosal, NV, OM, orphan, painful, palliative, randomized, ratio, regenerate, regimen, rinse, rinsing, solution, symptom, therapy, throat, tolerability, topically, track, treating, Trefoil, Type, ulceration, undergoing, Union, unmet, unreasonably

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

OGEN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

Certification of Chief Financial Officer

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

In connection with the Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 (the “Report”) of Oragenics, Inc. (the “Registrant”), as filed with the Securities and Exchange Commission on the date hereof, I, Michael Sullivan, hereby certify, to the best of my knowledge, that:

	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

	/s/ Michael Sullivan
Name:	Michael Sullivan
	Chief Financial Officer

Date:	August 14, 2020